Pfizer, BioNTech Score Fast Track Status For Covid-19 Vaccine Candidates

Pfizer Inc (PFE) and BioNTech SE (BNTX) have announced that two of the companies’ four investigational Covid-19 vaccine candidates from their BNT162 mRNA-based vaccine program have received Fast Track designation from the U.S. Food and Drug Administration (FDA).Shares in Pfizer are up 3% in Monday’s pre-market trading, while BioNTech has soared 9%.The two candidates, BNT162b1 and BNT162b2, are the most advanced vaccine candidates in the BNT162 program currently being evaluated in ongoing Phase 1/2 clinical studies in the United States and Germany.Fast Track is a process designed to facilitate the development, and expedite the review, of new drugs and vaccines …read more

Source:: Yahoo Finance